Susan Buchbinder
San Francisco Department of Public Health and University of California San Francisco · San Francisco Department of Public Health · Bridge HIV, San Francisco Department of Public Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Susan Buchbinder as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:09 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07658976 · Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated StrategyHIV Prevention Trials Network · not yet recruiting · HIV Infection, Sexually Transmitted Infection · study chair
- N/ANCT07510048 · Combatting HIV Or Other STIs Early (CHOOSE)Westat · recruiting · HIV, STIs, STIs Prevention · study chair
- N/ANCT07146139 · MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender WomenPublic Health Foundation Enterprises, Inc. · terminated · HIV Pre-exposure Prophylaxis, HIV Prevention and Care, Mobile Health Technology (mHealth) · principal investigator
- N/ANCT05474313 · A Study Evaluating An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM and TGWPublic Health Foundation Enterprises, Inc. · unknown · HIV Prevention, Pre-exposure Prophylaxis (PrEP), Risk Reduction · principal investigator
- Ph4NCT03771638 · DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young MenPublic Health Foundation Enterprises, Inc. · completed · Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis · principal investigator
- Ph1NCT03505060 · Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected AdultsNational Institute of Allergy and Infectious Diseases (NIAID) · withdrawn · HIV Infections · study chair
- Ph4NCT03387462 · DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP AdherencePublic Health Foundation Enterprises, Inc. · completed · Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis · principal investigator
- N/ANCT03138135 · HOME Study: a Combination Support Package to Increase Uptake of PrEP and HIV/STI TestingPublic Health Foundation Enterprises, Inc. · completed · HIV Prevention, Sexually Transmitted Diseases, Pre-Exposure Prophylaxis · principal investigator
- Ph1NCT01571960 · Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive AdultsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections · study chair
- Ph2NCT00131677 · Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative MenCenters for Disease Control and Prevention · completed · HIV Infection · principal investigator
- Ph1NCT00000929 · A Study of the Effects of Advantage 24 on the RectumNational Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections · study chair
- N/ANCT00001121 · A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1National Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- San Francisco Bay Clinical Trials Unit (CTU)UM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2012 to 2026 · $105,420 awarded in 2026Same name and institution; not confirmed by an ID
- MyPrEP Plus: Development and Pilot Testing of Novel Pre-Exposure Prophylaxis Support Tools for Transgender WomenR34MH132405 · NIMH · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2023 · $521,875 awarded in 2023Same name and institution; not confirmed by an ID
- PrEP-3D: An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSMR01MH119956 · NIMH · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2019 to 2023 · $471,332 awarded in 2023Same name and institution; not confirmed by an ID
- DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherenceR01MH109320 · NIMH · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2015 to 2018 · $760,876 awarded in 2018Grant number is on one of their registry trials
- HOME: A Comprehensive HIV Testing and Linkage Package for Young MSM of ColorR01AI104309 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2012 to 2016 · $547,518 awarded in 2016Grant number is on one of their registry trials
- Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk BR01DA031678 · NIDA · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2011 to 2013 · $531,920 awarded in 2013Same name and institution; not confirmed by an ID
- Prevention Umbrella for MSM in the AmericasR01AI083060 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2009 to 2012 · $610,604 awarded in 2012Same name and institution; not confirmed by an ID
- San Francisco Vaccine and Prevention UnitU01AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2007 to 2011 · $1,397,615 awarded in 2011Same name and institution; not confirmed by an ID
- SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNITU01AI048022 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · fiscal years 2000 to 2006 · $392,638 awarded in 2006Same name and institution; not confirmed by an ID
- HVTN 052: HIV-1 DNA PLASMID VACCINE AT 2 DIFFERENT DOSINGS IN HIV-1-UNINFECTED AM01RR000079 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2004 to 2005 · $35,510 awarded in 2005Same name and institution; not confirmed by an ID
- TRIAL OF LIVE (PRIVATE) RECOMBINANT CANARYPOX ALVA-HIV VCP205 IN HIVM01RR000083 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1998 to 2000 · $564 awarded in 2000Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- HIV Prevention Trials Network Leadership and Operations CenterUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe, WAFAA M. EL-SADR, RAPHAEL J LANDOVITZ · fiscal years 2011 to 2026Named on NCT07658976
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:09 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- 4,251 citationsRCR 138.3
- 1,396 citationsRCR 30.4
- Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Sci Transl Med · 2012865 citationsRCR 32.1
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.N Engl J Med · 2021551 citationsRCR 28.1
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.N Engl J Med · 2013482 citationsRCR 13.4
- 406 citationsRCR 59.9
- 341 citationsRCR 10.1
- 307 citationsRCR 7.2
- Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.Antimicrob Agents Chemother · 2017259 citationsRCR 12.8
- High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study.Am J Public Health · 2003256 citationsRCR 8.8